Phaseline

Targets › FNTA

FNTA (Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK…. (UniProt, P49354)

Open in Phaseline: the race on FNTA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Tipifarnib
Protein farnesyltransferase inhibitor
FNTA, FNTBPhase 2Malignant Solid NeoplasmSep 2027
Giselle ShollerTipifarnib
Protein farnesyltransferase inhibitor
FNTA, FNTBPhase 2NeuroblastomaDec 2030
Kura OncologyDarlifarnib
Farnesyltransferase inhibitor
FNTAPhase 1Solid Tumors With HRAS AlterationsJan 2027

Conditions

Malignant Solid Neoplasm (1) Solid Tumors With HRAS Alterations (1) Neuroblastoma (1)

Modalities

small molecule (2), mixed (1)

Companies

National Cancer Institute (NCI) (1) Kura Oncology (1) Giselle Sholler (1)

Related targets

FNTB (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.